Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published in 2011

There are 502 items in the Healthy Skepticism Library that were published in 2011.

Page 2 of 6 pages  < 1 2 3 4 >  Last ›

Hadley M
Federal Court: SensaSlim’s funds stay frozen
Australian Skeptics 2011 Jun 23

Independent Doctors’ group Formindep wins two-year battle against French Health Authority (HAS) over conflicts of interests
FormIndep 2011 Jun 20

Umanadh JBS
Driven by poverty, AP women turn ‘guinea pigs’
The Deccan Herald 2011 Jun 19

Dayton L
Disputed remedy in the dock: a defamation case highlights the need to tighten regulation of complementary medicines
The Australian 2011 Jun 18

Vollenweider D, Boyd CM, Puhan MA
High prevalence of potential biases threatens the interpretation of trials in patients with chronic disease
BMC Medicine 2011 Jun 13; 9:73

Braillon A
Mediator: who's to blame?
The Lancet 2011 Jun 11; 377:(9782):2003 - 2004

Hsu J, Brozek JL, Terraciano L, Kreis J, Compalati E, Stein Atetelboom, Fiocchi A, Schunemann HJ
Application of GRADE: Making Evidence-Based Recommendations about Diagnostic Tests in Clinical Practice Guidelines
Implementation Science 2011 Jun 10; 6:62

GSK discloses payments to Australian healthcare professionals
GlaxoSmithKline 2011 Jun 6

Dunlevy S
High-priced generics push out new drugs
The Australian 2011 Jun 4

La Rosa Rodríguez E
Los conflictos de intereses
Acta Bioethica 2011 Jun; 17:(1):47-54

HAI Europe
Hai Europe Response Consultation Response on Health Theats
HAI Europe 2011 May 30

Lai NM, Teng CL
Self-perceived competence correlates poorly with objectively measured competence in Evidence Based Medicine among medical students
BMC Medical Education 2011 May 28; 11:(25):

Tamiflu questions (Can only be viewed in Canada) Player 2011 May 240

Zalac F, Tinari S, Bartlett S
CBC Tamiflu probe sparks drug policy review
CBC News 2011 May 23

Bates A
Dr. Bates’ Talkback: How to get more value from existing products 2011 May 23

Dayton L
Fat chance of getting slim with 'fad pills'
The Australian 2011 May 20

Think yourself better
The Economist 2011 May 19

There is no alternative
The Economist 2011 May 19

Farr L
Sex life, weight loss, blood pressure medicines 'avoid official testing'
Adelaide Now 2011 May 18

HAI Europe
Civil Society Statement on Conflicts of Interest and the Future of Financing for WHO
HAI Europe Staff Blog 2011 May 17

Grant Steen R
Retractions in the medical literature: how many patients are put at risk by flawed research?
J Med Ethics 2011 May 17; 37:(11):

McNamara S
CPD: pharma should pay not sway
MJA InSight 2011 May 16

Fife-Yeomans J
Beware of snake oil salesmen
The Daily Telegraph 2011 May 14

Godlee F
Who should define disease?
BMJ 2011 May 11; 342:

Parliament’s stand against conflicts of interest: Is it enough to ensure medicines safety?
HAI 2011 May 10

Paliwal A
Policy draft backs new, expensive vaccines
Down To Earth 2011 May 10

Tabas JA, Boscardin C, Jacobsen DM, Steinman MA, Volberding PA, Baron RB
Clinician Attitudes About Commercial Support of Continuing Medical Education
Arch Intern Med 2011 May 9; 171:(9):840

Taylor L
US attacks on New Zealand drug agency draw anger
PharmaTimes 2011 May 9

Joelving F
Doctors loath to pay for unbiased education: survey
Reuters 2011 May 9

Dickinson A
Queenslanders put lives on line by ordering dangerous counterfeit drugs over the internet
The Courier-Mail 2011 May 9

Phadke A, Bhargava A
Towards universal health coverage in India
The Lancet 2011 May 7; 377:(9777):1569

Binning D
Proving cheaper drugs just as safe: Peter Simpson says the products his company makes are as good as the originals
The Australian 2011 May 7

Edwards J
How M.S. Drugs Are Promoted: 'We Have a Whole Money Laundering Thing Going On'
BNet 2011 May 6

Watson R
New European rules require all herbal medicines to be registered
BMJ 2011 May 6; 342:

BUKO Pharma, Health Action International, Institute of Public Health
At any price? - Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in India
Pharma Brief Special 2011 May 61:

Husten L
ACC CEO Jack Lewin Provides The Argument Against Industry Money
Cardio Brief 2011 May 6

Watson C
Diet pills pose danger
Adelaide Now 2011 May 5

Goldberg NH, Schneeweiss S, Kowal MK, Gagne JJ
Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States
JAMA 2011 May 4; 305:(17):1786

Tsai AC, Rosenlicht NZ, Jureidini JN, Parry PI, Spielmans GI, Healy D
Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature
PLoS Med 2011 May 3;

Rangarajan R
26 measels vaccine deaths in 3 years, but no action taken
The Times of India 2011 Apr 29

Brhlikova P, Harper I, Jeffery R, Rawal N, Subedi M, M R S.
Trust and the Regulation of Pharmaceuticals: South Asia in a Globalised World.
Global Health 2011 April 29; 7:(1):10

Treat S
Legislators Keenly Interested in Outcome of U.S. Supreme Court Case Challenging Vermont Law Protecting Private Prescription Records
NLARx Blog 2011 Apr 25

Johnson & Johnson Turns its Back on AIDS Patients
Medicins Sans Frontieres 2011 Apr 25

Rogers T, Norton MI.
The artful dodger: Answering the wrong question the right way.
J Exp Psychol Appl 2011 April 25;

Singer N
A Fight Over How Drugs Are Pitched
The New York Times 2011 Apr 24

Borges R
O trem da alegria dos laboratórios
Brasil 247 2011 Apr 24órios.htm

Office of the Attorney General The State of Vermont
Prescribed Products
2011 Apr 23

Colyer S
Court finds alternative cancer therapy claims not misleading
Oncology Update 2011 Apr 21

Jarvinen TLN, Sievanen H, Kannus P, Jokihaara J, Khan KM
The true cost of pharmacological disease prevention
BMJ 2011 Apr 20; 342:

Blackburn W
Future Pharma: A closer look at the iPad in pharma/physician relations 2011 Apr 20

Fauber J
UW group ends drug firm funds
The Journal Sentinel 2011 Apr 20

O'Donoghue N
Pharmacies face advertising investigations
Pharmacy News 2011 Apr 19

Caruana CM
Future pharma: Pharma’s new high-tech toolkit 2011 Apr 19

Hendel J
Future pharma: What near field communication (NFC) means for pharma 2011 Apr 19

Tolve A
Future pharma: Making games work for pharma 2011 Apr 19

Kaplan RM, Babad YM
Balancing influence between actors in healthcare decision making
BMC Health Services Research 2011 04 19; 11:(85):

Ricardo Cardoso P
MED & CINE - Dr. Paulo Ricardo Cardoso: Influência da Indústria Farmacêutica sobre os Médicos
Museu de História da Medicina 2011 Apr 180

Santana S, Lausen B, Bujnowska-Fedak M, Chronaki CE, Prokosch H-U, Wynn R
Informed citizen and empowered citizen in health: results from an European survey
BMC Family Practice 2011 Apr 16; 12:(20):

Rola farmaceuty w marketingu
PolishPharma 2011 Apr 12,-a7,1

Boniello K
'Face'-off in Prozac ad lawsuit
New York Post 2011 Apr 10

Wright D
Highlights from SFE Europe 2011 2011 Apr 8

Sansom C
Personalized medicine: Lesson for Oncology 2011 Apr 8

Silverman E
Should Social Media Shackles Come Off Pharma?
Pharmalot 2011 Apr 7

Silverman E
Antidepressants, Breast Cancer & Industry Studies
Pharmalot 2011 Apr 7

Silverman E
Did Drugmakers Violate India’s Patent Laws?
Pharmalot 2011 Apr 7

Mukherjee R
Drug MNCs violating patent law?
The Times of India 2011 Apr 7

Silverman E
Whistleblower Lawsuits And Off-Label Marketing
Pharmalot 2011 Apr 6

Edwards J
Why Do Bloomberg and AP Want to Look at Your Medical Records?
BNet 2011 Apr 6

Thacker P
Ghostwriting controversy haunting the American Psychiatric Association
Project On Government Insight 2011 Apr 5

Thacker P
American Psychiatric Association Spooked about Ghostwriting
Project On Government Insight 2011 Apr 5

Carroll B
Who You Gonna Believe?
Health Care Renewal Blog 2011 Apr 5

Carlat D
Like a Bad Penny, the Nemeroff/Schatzberg 'Textbook' Problem Returns
The Carlat Psychaitry Blog 2011 Apr 5

Silverman E
American Psychiatric Association And Ghostwriting
Pharmalot 2011 Apr 5

Kesselheim AS, Mello MM, Studdert DM
Strategies and Practices in Off-Label Marketing of Pharmaceuticals: A Retrospective Analysis of Whistleblower Complaints
PLoS Med 2011 Apr 5; 2Fjournal.pmed.1000431

Mack J
Brits Beat FDA & PhRMA: Issue Social Media Guidance for Pharma. This BI Tweet May Not Pass Muster.
Pharma Marketing Blog 2011 Apr 5

Dyer C
New code requires doctors to disclose all links with drug industry
BMJ 2011 Apr 5; 342:

Bass A
A tale of censorship and secrecy starring the American Psychiatric Association
Alison Bass 2011 Apr 4

Silverman E
Novartis, Gleevec And A Patent Dispute In India
Pharmalot 2011 Apr 4

Silverman E
University Researchers & The Spread Of Pain Meds
Pharmalot 2011 Apr 4

Zielinska E
Medical posters as art
The Scientist 2011 Apr 1

Patient Groups, Former HHS Secretaries, U.S. Chamber of Commerce, and More Than 50 Key Healthcare Stakeholders and Researchers Urge Supreme Court to Reject Three State Laws Outlawing Commercial Use of Prescription Data
Pharma Live 2011 Apr 1

Shrank WH, Liberman JN, Fischer MA, Avorn J, Kilabuk E, Chang A, Kesselheim AS, Brennan TA, Choudhry NK
The consequences of requesting 'dispense as written'.
Am J Med 2011 Apr; 124:(4):309-17

Stuckler D, Basu S, McKee M
Global Health Philanthropy and Institutional Relationships: How Should Conflicts of Interest Be Addressed?
PLoS Med 2011 Apr; 8:(4):

The World Medicines Situation Report 2011
World Health Organisation 2011 Apr

The World Medicines Situation Report 2011
World Health Organisation 2011 Apr

Wells WA, Brooks A
Adoption of New Health Products in Low and Middle Income Settings: How Product Development Partnerships Can Support Country Decision Making
Health Research Policy and Systems 2011 Mar 31; 9:(15):

New Research Shows MDs Prefer a Mix of Digital, Face-to-Face Marketing
Pharma Live 2011 Mar 31

Silverman E
What Doctors Do With Their Smartphones
Pharmalot 2011 Mar 31

Iskowitz M
GSK paid $57 mil. to doctors for speaking and advising in '10
Medical Marketing & Media 2011 Mar 31

Lai NM, Teng CL, Lee ML
Interpreting systematic reviews: are we ready to make our own conclusions?: A cross-sectional study
BMC Medicine 2011 Mar 30; 9:(30):

Tricco AC, Straus SE, Moher D
How can we improve the interpretation of systematic reviews?
BMC Medicine 2011 Mar 30; 9:(31):

Novo Nordisk, Eli Lilly, Grünenthal and Napp named in advertisements for breaches of the UK ABPI Code of Practice
Pharma Gossip 2011 Mar 30

Loftus P
Merck Paid $20.4 Million in Speaking Fees to U.S. Doctors
Market Watch 2011 Mar 30

Taylor L
EU consults on drug pricing/reimbursement decisions
Pharma Times 2011 Mar 30

Schwartz M
FDA again delays promised social media guidance
Medical Marketing & Media 2011 Mar 30

Avorn J.
Teaching Clinicians about Drugs — 50 Years Later, Whose Job Is It?
NEJM 2011 Mar 30;

Pfizer Collaboration With Apple/FDA: A Strategic Shift to Scientific Content in Marketing
Seeking Alpha 2011 Mar 30

Silverman E
Novo Nordisk Reprimanded For Poor Management
Pharmalot 2011 Mar 30

Silverman E
Conflicts Of Interest & Treatment Guideline Panels
Pharmalot 2011 Mar 29

Wilson D
Study Finds Conflicts Among Panels’ Doctors
The New York Times 2011 Mar 29

Page 2 of 6 pages  < 1 2 3 4 >  Last ›


  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Click to Register

(read more)

Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909